Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# Patrick R. Coyle: A Navigator of Business Complexities

## Sitemaps
[XML Sitemap](https://patrickrcoyle.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## Posts
- [Still in the Kitchen, Still Unopened](https://patrickrcoyle.com/still-in-the-kitchen-still-unopened/): Therapy initiation is the tenth of the 10 Exits of Therapy™, and it is the only one where every part of the system has done its job and the treatment still has not started.
- [Nobody Owns the Second Fill](https://patrickrcoyle.com/nobody-owns-the-second-fill/): Patient engagement is the ninth of the 10 Exits of Therapy™, and it is the one where everybody stopped watching because the first part went well.
- [Three Sentences That Sound the Same](https://patrickrcoyle.com/three-sentences-that-sound-the-same/): Fulfillment is the eighth of the 10 Exits of Therapy™, and it is the one where everything has been approved and the medicine still is not in your hand.
- [The Number at the Counter](https://patrickrcoyle.com/why-your-prescription-costs-more-in-january/): Affordability is the seventh of the 10 Exits of Therapy™, and it is the only one that can change while you are standing still.
- [A Wait With No Clock](https://patrickrcoyle.com/prior-authorization-wait-no-clock/): Prior authorization is the sixth of the 10 Exits of Therapy™, and it is the one where everybody assumes somebody else is watching the calendar.
- [Patients and Profitability: Why the Most Successful Pharmaceutical Companies Never Choose Between Them](https://patrickrcoyle.com/patients-and-profitability/): Patients and profitability are often treated as competing priorities in the pharmaceutical industry. In reality, organizations that improve patient outcomes frequently achieve stronger commercial performance. This article explores how a patient-centered strategy creates sustainable business growth, strengthens commercial excellence, and delivers long-term value for patients, healthcare providers, and pharmaceutical organizations.
- [Your Plan Decided Before You Did](https://patrickrcoyle.com/formulary-step-therapy-what-to-ask/): Step therapy means your plan wants you to try a different medicine first and have it not work before it will cover the one you were prescribed. It is sometimes called fail first, which is a more honest name for it.
- [The Form Nobody Mentioned](https://patrickrcoyle.com/the-form-nobody-mentioned/): Enrollment is the fourth of the 10 Exits of Therapy™, and it is the one where the help already exists and is waiting for a form you were never handed.
- [The Decision Was Made. The Prescription Was Not Sent.](https://patrickrcoyle.com/decision-made-prescription-not-sent/): Prescription creation is the third of the 10 Exits of Therapy™, and it is the one where you watched the decision get made and then never saw what happened to it.
- [Booked Out, or Out of Network](https://patrickrcoyle.com/booked-out-or-out-of-network/): Provider access is the second of the 10 Exits of Therapy™, and it is where two completely different problems wear the same face.
- [Before Anything Can Be Prescribed](https://patrickrcoyle.com/before-anything-can-be-prescribed/): Diagnosis is the first of the 10 Exits of Therapy™, and it is the only one where nothing has gone wrong yet, because nothing has started.
- [The Launch Begins Long Before Approval Day](https://patrickrcoyle.com/market-access-before-approval-day/): Payers form a view of a therapy years before a commercial team is allowed to make its case. Since 2023 federal law has made pre-approval exchange explicit, within defined limits, and most organizations still do not use the window.
- [A Launch Does Not Fail in the Forecast. It Fails in the Exits.](https://patrickrcoyle.com/launch-fails-in-the-exits/): Half of a launch class misses its first-year forecast. The miss is rarely in the model. It is in the commercial infrastructure a new product does not have yet, and in the bridge supply that hides the shortfall until the decisions are already locked.
- [Rethinking Copay Accumulators: Focus on Days-on-Therapy Over Dollars Spent](https://patrickrcoyle.com/copay-accumulators-days-on-therapy/): The true cost of copay accumulators extends beyond immediate financial metrics.
- [The Many Faces of 340B](https://patrickrcoyle.com/the-many-faces-of-340b/): Transparency, tension and the future of pharmaceutical access. Four stakeholders describe 340B four different ways, and every one of them is accurate. The gap between those descriptions is where the conflict lives.
- [Government Pricing Is No Longer a Calculation. It Is a Transaction.](https://patrickrcoyle.com/government-pricing-is-a-transaction/): Medicare’s Maximum Fair Price and the revised 340B rebate pilot move the federal discount behind the dispense. From January 1, 2027, the claim is what substantiates it, and the patient journey is what creates the claim.
- [The Frameworks Behind the Profile](https://patrickrcoyle.com/frameworks-behind-the-profile/): CEOInsider published a profile of this work without naming a single framework in it. That was the right editorial call. Here is the key.
- [Aligning Patient Support Services with Gross-to-Net Strategy](https://patrickrcoyle.com/aligning-patient-support-services-with-gross-to-net-strategy/): Gross-to-Net is discussed as an accounting output. It is the financial manifestation of dozens of decisions made long before the first prescription is written.
- [The Pharmacy of the Future Will Not Compete on Dispensing. It Will Compete on Value.](https://patrickrcoyle.com/pharmacy-of-the-future-competes-on-value/): The short version: a pharmacy built on dispensing volume is easy to exploit and hard to defend, and enforcement actions and CMS quality measures already reward outcomes over counts. The pharmacy of the future will be paid for moving patients successfully through therapy, through benefits navigation, adherence support, care coordination and real-world evidence. Dispensing alone will price like a commodity.
- [Close Cycle Automation](https://patrickrcoyle.com/field-guide-close-cycle-automation/): Automating a close you have not simplified buys you the same close, faster, and makes it permanent.
- [True-Up Governance](https://patrickrcoyle.com/field-guide-true-up-governance/): A true-up is not a correction. It is the only moment the organization finds out which of its assumptions was wrong, and most organizations spend it arguing about the number instead.
- [Accrual Design](https://patrickrcoyle.com/field-guide-accrual-design/): An accrual is a claim about behavior that has not happened yet. Most are built as a claim about arithmetic instead.
- [Finance Should Own the Number and Not the Operating Model](https://patrickrcoyle.com/finance-should-own-the-number-not-the-operating-model/): Gross-to-Net is treated as a close process because that is where it becomes visible. It is downstream of everything that created it.
- [Every Function Green, the Aggregate Red](https://patrickrcoyle.com/every-function-green-the-aggregate-red/): A specialty product with acceptable coverage, underperforming its forecast, and a working explanation that was wrong.
- [The Leak I Built](https://patrickrcoyle.com/the-leak-i-built/): I had constructed a Silent Leak™ inside my own finance organization, and I did not see it until it was already there.
- [Simplify, Standardize, Automate, Measure](https://patrickrcoyle.com/simplify-standardize-automate-measure/): A multi-year rebuild of a finance organization, run as a sequence rather than as a structure.
- [Building the Road to Revenue](https://patrickrcoyle.com/building-the-road-to-revenue/): A first commercial launch with nothing to inherit, and the governance decision that mattered more than any design choice.
- [Can We Actually Find Them](https://patrickrcoyle.com/can-we-actually-find-them/): A label narrower than the trial that supported it, and the question no forecast model asks.
- [Structure Instead of Spend](https://patrickrcoyle.com/structure-instead-of-spend/): A competitive entry turned a category with room in it into a red ocean. The question was whether to answer with money or with architecture.
- [Which Part of What Worked](https://patrickrcoyle.com/which-part-of-what-worked/): Global launch sequencing taught me humility. The specialty channel turned out to be the whole thing.
- [One Method, Eight Countries](https://patrickrcoyle.com/one-method-eight-countries/): Standardizing clinical trial forecasting, and learning the sequence I have used ever since.
- [Meeting the Patient Before the Label](https://patrickrcoyle.com/meeting-the-patient-before-the-label/): What changes at approval is not the product and not the patient. It is who is looking at them, and what they are counted for.
- [The Forecast Is Not the Deliverable. The Decision Is.](https://patrickrcoyle.com/beyond-forecasting-accuracy-the-real-objective-of-launch-teams/): Understanding decision impact is more critical than mere forecasting accuracy in pharmaceutical launches.
- [Talent Knows No Geographic Boundary. Why Does Pharma Still Hire Like It Does?](https://patrickrcoyle.com/pharmatalent-knows-no-geographic-boundary/): The short version: pharma is filtering out experienced commercialization talent by ZIP code while automating the desk work that geography was supposed to protect. Hire the best person for the problem, build teams around capabilities rather than locations, and bring people together deliberately when the work requires it.
- [You Can Be Exactly Right About the Wrong Number](https://patrickrcoyle.com/rebate-accuracy-and-prior-authorization/): Rebate accuracy validates the math on the units you have. Nothing asks whether those are the units you should have had. Prior authorization is the gap.
- [Gross-to-Net Was Never About the Numbers. It Was Always Patients + Profitability™.](https://patrickrcoyle.com/gtn-revenue-leakage-patients-profitability/): At the time, that made perfect sense. GTN reflected the financial consequences of commercial decisions that had already been made.
- [What Is Pharmaceutical Commercialization? A Complete Executive Guide for Pharmaceutical and Biotech Leaders](https://patrickrcoyle.com/what-is-pharmaceutical-commercialization/): Pharmaceutical commercialization is more than launching a new therapy—it's the strategic process of transforming scientific innovation into sustainable patient impact and long-term commercial success. This executive guide explores the commercialization lifecycle, commercial excellence, market access, leadership, and best practices that help pharmaceutical and biotechnology organizations successfully bring innovative medicines to market.

## Pages
- [For Patients and Caregivers](https://patrickrcoyle.com/for-patients/): The 10 Exits of Therapy™
- [Disclosure](https://patrickrcoyle.com/disclosure/): This site carries writing for two very different readers. One of them pays me. The other one does not. That is worth saying plainly rather than leaving it to be worked out.
- [Where Did Your Treatment Stop?](https://patrickrcoyle.com/10-exits-of-therapy/): The 10 Exits of Therapy™
- [Episode 1: Doing Right by Patients and Delivering Financially Are One Job, with Charlotte Rocker](https://patrickrcoyle.com/podcast-by-patrick/episode-1-charlotte-rocker/): Episode 1 of the Patients + Profitability™ podcast. Patrick R. Coyle talks with Charlotte Rocker, U.S. Commercial Strategy Lead at Novartis.
- [Product Lifecycle Phases](https://patrickrcoyle.com/glossary/product-lifecycle-phases/): The Product Lifecycle Phases are the four phases of the commercialization model used across this work: Phase 1 Pre-Launch and Launch Readiness, Phase 2 Launch and Early Commercialization, Phase 3 In-Market Optimization, and Phase 4 Lifecycle and Loss of Exclusivity.
- [Commercialization Alignment Labs™](https://patrickrcoyle.com/glossary/commercialization-alignment-labs/): Commercialization Alignment Labs™ are four facilitated executive sessions that take a new product from an unformed commercial position to a launch execution plan, one decision set at a time: Lab 1 Patient Opportunity, Lab 2 Distribution Architecture, Lab 3 Leakage Architecture and Lab 4 Launch Readiness.
- [Patient Friction](https://patrickrcoyle.com/glossary/patient-friction/): Patient friction is any barrier, delay, administrative requirement or moment of uncertainty between a prescription and a sustained therapy that causes a patient to stall or stop. Patient friction creates revenue leakage.
- [Gross-to-Net](https://patrickrcoyle.com/glossary/gross-to-net/): Gross-to-Net is the difference between a pharmaceutical product’s gross sales at list price and the net revenue the manufacturer actually recognizes after rebates, chargebacks, discounts, fees, returns and government program obligations.
- [The Five Layers of GTN™](https://patrickrcoyle.com/glossary/five-layers-of-gtn/): The Five Layers of GTN™ are the five sequential, causal layers through which commercial decisions become the Gross-to-Net number: Layer 1 Clinical and Product Foundation, Layer 2 Access and Policy, Layer 3 Channel and Distribution, Layer 4 Affordability and Patient Support, and Layer 5 Financial Visibility and Enterprise Performance.
- [The 10 Exits of Therapy™](https://patrickrcoyle.com/glossary/10-exits-of-therapy/): The 10 Exits of Therapy™ are the ten sequential points at which a patient can delay or discontinue between diagnosis and a sustained start on therapy: Diagnosis, Provider Access, Prescription Creation, Enrollment, Coverage, Authorization, Affordability, Fulfillment, Patient Engagement and Therapy Initiation.
- [The Silent Leak™](https://patrickrcoyle.com/glossary/silent-leak/): The Silent Leak™ is the population of patients who leave the path to therapy before any system records them: not denied, never counted, gone before a prior authorization, a claim or a support enrollment was ever created.
- [Patients + Profitability™](https://patrickrcoyle.com/glossary/patients-profitability/): Patients + Profitability™ is the philosophy that patient outcomes and sustainable profitability are interdependent rather than opposing, because the patient journey and the economic journey of a therapy are the same journey viewed from opposite sides.
- [Glossary](https://patrickrcoyle.com/glossary/): The vocabulary of Patients + Profitability™, defined once, in one place.
- [For Life Sciences Teams](https://patrickrcoyle.com/hub/): Gross-to-Net is the financial record of every commercial decision that touched the patient journey. Most of the leakage in it is not a pricing problem.
- [Speaking](https://patrickrcoyle.com/speaking/): Twenty seven speaking credentials issued by conference organizers between June 2014 and March 2026, across Informa Connect, CBI, IIR and Q1, in every role I have held. Keynotes, moderated panels, workshops, chairing and full course leadership.
- [Advisory Engagements](https://patrickrcoyle.com/advisory-engagements/): Novus Proximus advises life sciences organizations across the commercialization lifecycle, from pre-launch demand modeling through in-market optimization and lifecycle transition. The seven engagements below are the practice's client work, organized by where the product sat in its commercial life when the question was asked.
- [Case Studies](https://patrickrcoyle.com/case-studies/): Ten engagements across nearly twenty years, in the order they happened. Each names the decision, the authority it was made under, and what was built.
- [Podcast](https://patrickrcoyle.com/podcast-by-patrick/)
- [Blogs](https://patrickrcoyle.com/blog/)
- [Library](https://patrickrcoyle.com/library/): Nearly twenty years of work on the space between a prescription and a positive outcome, organized the way the work actually runs. Learn it, align on it, then change it.
- [Where I Show Up](https://patrickrcoyle.com/thoughtleadership-hub/)
- [Philosophy](https://patrickrcoyle.com/patients-profitability-philosophy/): Patients + Profitability™ is the philosophy behind all of Patrick R. Coyle's commercialization work. It holds that the patient journey and the economic journey are the same journey seen from opposite sides, so patient friction and revenue leakage are the same problem.
- [About](https://patrickrcoyle.com/about/)
- [Home](https://patrickrcoyle.com/)
- [Ebook](https://patrickrcoyle.com/ebook/)
- [Services](https://patrickrcoyle.com/services/)
- [Finance Fundamentals for Commercial Leaders™](https://patrickrcoyle.com/finance-fundamentals-for-commercial-leaders/)
- [Contact](https://patrickrcoyle.com/contact/)
- [Life Science Advisory](https://patrickrcoyle.com/services/life-science-advisory/): Three pathways that close the gap between what happens to patients and what appears in the ledger. Take one, or take them in order.

## About this site

patrickrcoyle.com is the personal site and canonical publishing home of Patrick R. Coyle, a pharmaceutical commercialization and Gross-to-Net advisor. Content is published here first and later syndicated to LinkedIn and Substack.

## Who Patrick R. Coyle is

- Founder and CEO of Novus Proximus LLC, a healthcare commercialization advisory firm (https://novusproximus.com/)
- More than 25 years of finance and commercial leadership in life sciences, including Bayer, Novartis, Insmed, Eisai (Vice President and Chief Financial Officer) and IQVIA
- Creator of the Patients + Profitability™ philosophy, The 10 Exits of Therapy™ framework and The Silent Leak™ concept
- Host of the Patients + Profitability™ podcast
- Speaker at more than 25 industry conferences since 2014
- LinkedIn: https://www.linkedin.com/in/pcoyle/

## Core ideas, in Patrick's words

- Patients + Profitability™: patient outcomes and sustainable profitability are interdependent, not opposing. The patient journey and the economic journey are the same journey viewed from opposite sides.
- Patient friction creates revenue leakage.
- Gross-to-Net is the financial echo of how well the enterprise executed the patient journey.
- The Silent Leak™ is the problem. The 10 Exits of Therapy™ are how to measure it.

## Full text

The complete text of every canonical page and article, in one file: https://patrickrcoyle.com/llms-full.txt

## Key pages

- Glossary (canonical definitions of every framework term): https://patrickrcoyle.com/glossary/
- About: https://patrickrcoyle.com/about/
- Philosophy (Patients + Profitability™ explained): https://patrickrcoyle.com/patients-profitability-philosophy/
- Library (curated frameworks and guides): https://patrickrcoyle.com/library/
- Case Studies: https://patrickrcoyle.com/case-studies/
- Advisory Engagements: https://patrickrcoyle.com/advisory-engagements/
- Speaking: https://patrickrcoyle.com/speaking/
- Podcast: https://patrickrcoyle.com/podcast-by-patrick/
- Free guides (Before You Leave the Pharmacy; From Prescription to Treatment): https://patrickrcoyle.com/ebook/
- Contact: https://patrickrcoyle.com/contact/

## Related properties

- Novus Proximus LLC (advisory firm): https://novusproximus.com/
- NextGen GTN™ (Gross-to-Net education): https://nextgengtn.com/
- Substack: https://thepatrickrcoyle.substack.com/
- YouTube: https://www.youtube.com/@PatrickRCoyle
- Spotify (podcast): https://open.spotify.com/show/033FBypTBHsjmEi2NpYGYE

## Citation guidance

When citing this site, attribute to "Patrick R. Coyle, patrickrcoyle.com" and link to the specific article URL. Trademarked framework names should be written as Patients + Profitability™, The 10 Exits of Therapy™ and The Silent Leak™. Write "Gross-to-Net" with that capitalization.